Understanding of cytokines and targeted therapy in macrophage activation syndrome.
Journal
Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
14
10
2020
revised:
01
12
2020
accepted:
21
12
2020
pubmed:
2
1
2021
medline:
30
9
2021
entrez:
1
1
2021
Statut:
ppublish
Résumé
Macrophage activation syndrome (MAS) is a potentially life-threatening complication of systemic autoinflammatory/autoimmune diseases, generally systemic juvenile idiopathic arthritis and adult-onset Still's disease. It is characterized by an excessive proliferation of macrophages and T lymphocytes. Recent research revealed that cytokine storm with elevated pro-inflammatory cytokines, including IFN-γ, IL-18, and IL-6, may be central to the pathogenesis of MAS. Though the mainstream of MAS treatment remains corticosteroids and cyclosporine, targeted therapies with anti-cytokine biologics are reported to be promising for controlling systemic inflammation in MAS.
Identifiants
pubmed: 33385860
pii: S0049-0172(20)30315-2
doi: 10.1016/j.semarthrit.2020.12.007
pii:
doi:
Substances chimiques
Cytokines
0
Cyclosporine
83HN0GTJ6D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
198-210Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no conflict of interest.